Evidence map›Paper›PMID 38036998›Full record

ArticleBMC microbiology2023

An attacin antimicrobial peptide, Hill_BB_C10074, from Hermetia illucens with anti-Pseudomonas aeruginosa activity.

Leila Fahmy, Youssif M Ali, David Seilly, Reece McCoy, Róisín M Owens, Miha Pipan, Graham Christie, Andrew J Grant

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Broadly Defined Antibiotic Adjuvants forThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Antimicrobial peptides: from discovery to developmental applications.Applied and environmental microbiology · 2025
    Review
  11. Drug Discovery Potential of Insect-derived Compounds: A Review.Current drug discovery technologies · 2025
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Leila FahmyDepartment of Veterinary Medicine, University of Cambridge, Cambridge, UK.
Youssif M AliDepartment of Veterinary Medicine, University of Cambridge, Cambridge, UK.
David SeillyDepartment of Veterinary Medicine, University of Cambridge, Cambridge, UK.
Reece McCoyDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Róisín M OwensDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Miha PipanBetter Origin, Future Business Centre, Cambridge, UK.
Graham ChristieDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Andrew J GrantDepartment of Veterinary Medicine, University of Cambridge, Cambridge, UK. ajg60@cam.ac.uk.
University of Cambridge · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M011194/1
6 · The paper itself

Abstract

backgroundThere is a global need to develop new therapies to treat infectious diseases and tackle the rise in antimicrobial resistance. To date, the larvae of the Black Solider Fly, Hermetia illucens, have the largest repertoire of antimicrobial peptides derived from insects. Antimicrobial peptides are of particular interest in the exploration of alternative antimicrobials due to their potent action and reduced propensity to induce resistance compared with more traditional antibiotics.

resultsThe predicted attacin from H. illucens, Hill_BB_C10074, was first identified in the transcriptome of H. illucens populations that had been fed a plant-oil based diet. In this study, recombinant Hill_BB_C10074 (500 µg/mL), was found to possess potent antimicrobial activity against the serious Gram-negative pathogen, Pseudomonas aeruginosa. Sequence and structural homology modelling predicted that Hill_BB_C10074 formed a homotrimeric complex that may form pores in the Gram-negative bacterial outer membrane. In vitro experiments defined the antimicrobial action of Hill_BB_C10074 against P. aeruginosa and transmission electron microscopy and electrochemical impedance spectroscopy confirmed the outer membrane disruptive power of Hill_BB_C10074 which was greater than the clinically relevant antibiotic, polymyxin B.

conclusionsCombining predictive tools with in vitro approaches, we have characterised Hill_BB_C10074 as an important insect antimicrobial peptide and promising candidate for the future development of clinical antimicrobials.

Indexed as

Anti-Infective AgentsDipteraAnimalsAnti-Bacterial AgentsAntimicrobial PeptidesInsect ProteinsPseudomonas aeruginosaAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Peptidesattacin antibacterial protein, insectInsect ProteinsAlphafoldAntibioticsAntimicrobial peptidesAttacinsHermetia illucensMembrane permeabilityPseudomonas aeruginosa

Identifiers

PMID38036998
PMCPMC10690985
OpenAlexW4389240821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.